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184Patient compliance limits the efforts of quality
improvement initiatives on arteriovenous ﬁstula
maturation
Susanna K. Lynch, BS, Sadaf S. Ahanchi, MD, David J. Dexter, MD, Marc H. Glickman, MD, and
Jean M. Panneton, MD, Norfolk, Va
Objective: Our institutional quality-improvement (QI) initiative instituted a well-deﬁned ofﬁce follow-up schedule after
arteriovenous ﬁstula (AVF) creation, including an ofﬁce visit within 30 days, ﬁstulogram within 40 days, if indicated, and
a second ofﬁce visit within 55 days. In addition, a patient liaison contacted patients and dialysis units to improve follow-
up. The purpose of this study was to determine the effect of the QI initiative on patient compliance and overall time to
AVF permission to cannulate.
Methods: We performed a retrospective review of patients undergoing ﬁrst-time radiocephalic, brachiocephalic, and basilic vein
transposition creation before the QI initiative (pre-QI group: January to April 2012) and during the QI period (QI group:
January toApril 2013).Categoric datawere comparedusingc2 analysis, andnominal datawere comparedusing theStudent t-test.
Results:We reviewed 198 ﬁrst-time AVF creations in patients (57% male) with a mean age of 61 years. Demographics and
comorbidities between the pre-QI and QI groups were similar. Compliance with the ﬁrst 30-day postoperative
appointment increased signiﬁcantly after the QI initiative, from 48% in the pre-QI group to 65% in the QI group
(P [ .015). Yet, the QI initiative did not maintain an effect on the subsequent follow-up checkpoints. No statistical dif-
ferencewas identiﬁed for compliance with ﬁstulogramwithin 40 days of access creation (pre-QI, 12% vsQI, 25%; P[ .093)
or for compliance with the 55-day postoperative appointment (pre-QI, 33% vs QI, 23%; P [ .457). Both checkpoints
demonstrated a very high noncompliance rate. Accordingly, the mean time to permission to cannulate was 88 days for both
the pre-QI andQI groups, with a failure to mature rate of 22% for the pre-QI group and 21% for the QI group (P[ .816).
Conclusions: The QI initiative signiﬁcantly increased the number of patients complying with the ﬁrst 30-day follow-up
appointment after AVF access creation. However, patient compliance with a timely ﬁstulogram and the second follow-
up appointment was poor and not inﬂuenced by the QI initiative, limiting the functional effect of the QI initiative on
the time to AVF permission to cannulate. (J Vasc Surg 2015;61:184-91.)Arteriovenous ﬁstulas (AVFs) are considered the gold
standard access for hemodialysis (HD) due to the decreased
risk of complications from infection and thrombosis, longer
patency, and lower cost compared with AV grafts (AVG) or
tunneled dialysis catheters (TDCs).1,2 Since its inception in
2003, the Fistula First Breakthrough Initiative (FFBI)
stressed the importance of increasing AVF use by setting a
AVF prevalence goal rate of 66% by 2009.3 Although AVF
placement has increased in the years after the FFBI, use of
AVFs in patients has plateaued, and patients initiating HD
therapy via a TDC remains as high as 80% in some areas.4
In addition to other AVF patient outcomes, decreasing
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://dx.doi.org/10.1016/j.jvs.2014.05.095mature rates remains a daunting task. Debate continues
throughout the literature over the best predictors of AVF
maturation and methods of increasing AVF maturation
and usage, and several expert panels have concluded that
only very low-quality data are guiding clinical HD access
placement. This is demonstrated by the lack of large ran-
domized controlled trials.5,6 The Kidney Disease Outcomes
and Quality Initiative (KDOQI) and FFBI have encour-
aged the use of formalized care pathways and patient data-
base management systems to meet the goals set by FFBI.
End-stage renal disease (ESRD) networks are expected to
identify beneﬁcial changes in protocol to promote best clin-
ical practices and use data-reporting systems to enable
monitoring of patient outcomes and complications.1,3
In 2008, our institution reported prolonged maturation
times, averaging 146 days for radiocephalic (RC) AVFs and
brachiocephalic (BC) AVFs, and a high failure to mature rate
of 37%.7 To address these shortcomings, a quality improve-
ment (QI) initiative was established in January 2013 that
included a standardized protocol of preoperative dialysis duplex
ultrasound imaging and follow-up schedule and a patient
liaison to contact patient and dialysis units to ensure follow-up.
Preoperative dialysis duplex ultrasound scans and ﬁstula
maturation duplex ultrasound imaging were already a stan-
dard part of our group’s practice but without a formal,
Fig 1. Sample form shows parameters measured during a ﬁstula maturation duplex ultrasound assessment.
JOURNAL OF VASCULAR SURGERY
Volume 61, Number 1 Lynch et al 185consistent, or enforced timeline. The preoperative dialysis
duplex ultrasound assessment provides superﬁcial vein
measurements (cephalic and basilic) at eight points along
the arm, including diameter and depth, as well as an arterial
analysis of the location of the brachial bifurcation with
brachial, radial, and ulnar artery velocities. The ﬁstula
maturation duplex ultrasound assessment measures access
vein depth at three points, diameter at three points, velocity
at seven points, and volume ﬂow at three points
throughout the access (Fig 1 shows a sample form). Both
elements were formally incorporated into the mandated
follow-up schedule, which was enforced by the patient
liaison during the QI period.
METHODS
After obtaining approval from theEasternVirginiaMed-
ical School Institutional Review Board, we used the Current
Procedural Terminology (American Medical Association,
Chicago, Ill) codes 36818, 36819, 36820, 36821, 36825,
and 36830 to query the practice’s billing database and
generate a list of patients who underwent AV access surgery
between January 1, 2012, and April 12, 2013. Patient con-
sentwas waived for thisminimal risk study and in compliance
with the Health Insurance Portability and Accountability
Act. Only ﬁrst-time AVF placements were included in the
review; patients who had undergone previous AV access sur-
gery or received an AVGwere excluded. Also excluded were
patients within the interim implementation and training
period for the QI (October to December 2012). Patients
with a temporary or TDC were not excluded.
Ofﬁce and hospital records were reviewed for patient de-
mographics, pertinent medical history, physical examination
ﬁndings, preoperative and postoperative duplex imaging,
and postoperative follow-up. Operative and intervention
notes were reviewed for relevant procedural ﬁndings and
complications. Information was deidentiﬁed and recorded
in a password-protected database (Microsoft Corp, Red-
mond, Wash). Two groups were compared: patients whohad AVF creation before the QI initiative (pre-QI group:
January to April 2012) and patients who had AVF creation
during the QI period (QI group: January to April 2013).
The QI initiative outlined a timeline for AVF access
creation (Fig 2). Previous studies have examined the
different components and timing of postaccess creation
follow-up, including determination of suitability for usage,
duplex usage, and ﬁstulogram usage.1,8-13 Our protocol
was developed based on a review of this literature, existing
institutional protocols, and collaborative efforts between
the surgeons, nursing and ofﬁce staff, dialysis unit man-
agers, and hospital management. Upon nephrologist
request or within 2 weeks of TDC placement, appoint-
ments were scheduled for a preoperative dialysis duplex
ultrasound assessment and a consultation with a vascular
surgeon to arrange for permanent access creation. The pre-
operative dialysis duplex ultrasound protocol was duplex
and Doppler imaging of the entire length of the cephalic
and basilic veins bilaterally to assess size, depth, and
patency. Waveforms, velocities, and B-mode imaging of
radial and brachial arteries was also performed.
After review of the dialysis duplex ultrasound images, the
vascular surgeonwould schedule andperformaﬁstula or graft
placement within 1 to 2 weeks. After the operation, the pa-
tient would undergo a ﬁstula maturation duplex ultrasound
assessment in our clinic within 2 to 3 weeks and then have
an appointment with the surgeon to review AVFmaturation
within 4weeks. If theﬁstula appeared tobematuring, the sur-
geon would give permission to cannulate immediately or
within 1 to 2 weeks, or would follow-up in a second appoint-
ment 2 weeks later with another. Any evidence of stenosis
resulted in a ﬁstulogram and possible intervention within
10 days. The patient was then scheduled for a second
follow-up appointment 2weeks after theﬁstulogramor inter-
vention, atwhich time the patient received permission to can-
nulate or underwent another intervention for maturation.
All scheduling and reminders of appointments were
done through the regular ofﬁce staff. The patient liaison
TDC 
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+ Vascular 
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AVF Access 
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+ Vascular 
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Vascular 
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Vascular 
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Fig 2. Timeline illustrates the standardized protocol for arteriovenous ﬁstula (AVF) creation from referral to
maturation. F/U, Follow-up; TDC, tunneled dialysis catheter.
236 
AVFs 
123 in 
pre-QI
113 
in QI
4 died 
before 
maturation
9 lost to f/u
110 AVFs 88 AVFs
7 died before 
maturation
10 lost to f/u
7 failed to mature 
before study 
closed
1 decided against 
care
31 RC AVFs
48 BC AVFs
31 BVTs
24 RC AVFs
45 BC AVFs
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Fig 3. Flow chart shows stratiﬁcation of all patients who under-
went arteriovenous ﬁstula (AVF) creation from January 1, 2012,
through April 30, 2012 (before the quality-improvement [pre-QI]
initiative), and from January 1, 2013, through April 12, 2013
(QI). Only patients who underwent ﬁrst-time autologous AVF
creation were included in the study. BC, Brachiocephalic; BVT,
basilic vein transposition; f/u, follow-up; RC, radiocephalic.
Table I. Patient demographics and comorbidities
Variablesa Pre-QI (n ¼ 110) QI (n ¼ 88) P
Male 60 (55) 53 (60) .422
Age, years 60 6 15 62 6 14 .477
BMI, kg/m2 31 6 8 31 6 8 .448
Race
African American 79 (72) 57 (65)
Caucasian 26 (24) 27 (31)
Hispanic 4 (3) 1 (1)
Asian/Paciﬁc Islander 1 (1) 3 (3)
Diabetes 71 (65) 62 (71) .448
Hypertension 108 (99) 86 (98) .587
ESRD on HD 75 (68) 58 (66) .762
Dyslipidemia 69 (63) 65 (74) .126
Tobacco use 67 (62) 49 (56) .467
CHF 40 (37) 25 (28) .227
BMI, Body mass index; CHF, congestive heart failure; ESRD on HD,
end-stage renal disease on hemodialysis; Pre-QI, ﬁstula creation before the
quality-improvement initiative was instituted; QI, ﬁstula creation after
quality-improvement initiative was instituted.
aCategoric data are shown as number (%) and continuous data as
mean 6 standard deviation.
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received a list of missed ofﬁce visits or duplex appointments
and called the patient to schedule a new appointment. If
the patient liaison could not get directly in touch with
the patient after two attempts and the patient was already
on HD, she called the dialysis unit to follow-up on the
patient’s progress. The unit coordinator, social worker, or
nephrologist talked to the patient, and if the patient was
willing, the appointment was rescheduled.
Primary end points were time to permission to cannu-
late, failure to mature, and death. Secondary end points
were intervention rate, compliance with protocol follow-
up appointments within 30, 40 and 55 days, and primary,
primary assisted, and secondary patency. Interventions
included percutaneous transluminal angioplasty, ligation,
coil embolization, thrombectomy, superﬁcialization, and
distal revascularization interval ligation.
Continuously distributed data were evaluated using the
independent-samples t-test, and categoric data were evalu-
ated using c2 analysis. Kaplan-Meier curves were used to
compare the patency between the pre-QI and QI cohorts.
Data were analyzed using IBM SPSS 21.0 software (IBM
Corp, Armonk, NY).
RESULTS
Demographics. AVFs were created in 236 patients:
123 from January 1, 2012, through April 30, 2012 (pre-
QI group), and 113 from January 1, 2013, through April
12, 2013 (QI group). Patient selection is illustrated in
Fig 3. The study excluded patients who died before
maturation, were lost to follow-up, decided against
continued care, and those in whom we were unable to
assess ﬁstula maturity by the close of the study. We
excluded these patients due to inability to assess compli-
ance. Those in whom we were unable to assess maturity by
the close of the study had a future scheduled appointment
past the date of the end of the study and the access has not
yet been abandoned or given permission to be cannulated.
Demographics and comorbidities of the study cohort
are listed in Table I. At the time of AVF creation, 68%
of the pre-QI patients were undergoing HD by a tempo-
rary or TDC compared with 67% of the QI cohort
(P ¼ .762). The pre-QI cohort was composed of 60
men (55%), with an average age of 60 years and a mean
body mass index of 31 kg/m2, and the QI cohort was
composed of 53 men (60%; P ¼ .422), with an averageage of 62 years (P ¼ .477) and mean body mass index
of 31 kg/m2 (P ¼ .448).
Preoperative and operative data. Of the 198 patients
included in the study cohort, 110 initial AVF accesses were
created during the pre-QI period: 31 RC (28%), 48 BC
Table II. Overall compliance and patient-related
outcomes
Variablea Pre-QI QI P
Compliance with 1st
appointment
53 (48) 55 (65) .029
Average days to 1st appointment 40.8 6 43.4 33.2 6 18.3 .099
Compliance with ﬁstulogram 2 (12) 11 (33) .173
Average days to ﬁstulogram 66 6 34 57 6 29 .324
Compliance with 2nd
appointment
18 (25) 15 (23) .842
Average days to 2nd
appointment
77 6 27 77 6 28 .907
Time to maturation, days 88 6 46 88 6 47 .920
Failure to mature 24 (22) 18 (21) .862
Mean number of interventions 0.42 0.61 .116
Mortality 6 (6) 4 (5) .772
Pre-QI, Fistula creation before the quality-improvement initiative was
instituted; QI, ﬁstula creation after quality-improvement initiative was
instituted.
aCategoric data are shown as number (%) and continuous data as mean 6
standard deviation.
Table III. Mean interventions per access by
arteriovenous ﬁstula (AVF) location, as indicated for
maturation
Variable Pre-QI QI P-value
RC AVF
PTA 0.61 0.48 .402
Thrombectomies 0.03 0.00 .325
Surgical revisions 0.03 0.00 .325
Branch ligations 0.00 0.09 .249
Coil embolizations 0.23 0.04 .044
Superﬁcializations 0.07 0.04 .738
BC AVF
PTA 0.38 0.63 .139
Thrombectomies 0.04 0.00 .165
Branch ligations 0.00 0.02 .310
Coil embolizations 0.13 0.20 .357
Superﬁcializations 0.00 0.04 .147
DRILs 0.04 0.02 .585
BVT
PTA 0.26 0.58 .051
Thrombectomies 0.07 0.00 .268
DRILs 0.00 0.05 .205
BC, Brachiocephalic; BVT, basilic vein transposition; DRIL, distal
revascularization-interval ligation; Pre-QI, ﬁstula creation before the quality-
improvement initiative was instituted; PTA, percutaneous transluminal an-
gioplasty; QI, ﬁstula creation after quality-improvement initiative was
instituted; RC, radiocephalic.
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AVF accesses were created: 24 RC (27%), 45 BC (51%),
and 19 (22%) BVT (c2 ¼ .487). Within the pre-QI cohort,
the mean vein size at the site of access creation on preop-
erative ultrasound imaging was 2.79 mm in RC AVFs,
3.19 mm in BC AVFs, and 3.28 mm in BVTs at mean
depths of 2.74 mm for RC AVFs and 3.51 mm for BC
AVFs. Within the QI cohort (compared with the pre-QI
cohort), the mean vein size was 2.91 mm in RC AVFs
(P ¼ .670), 3.88 mm in BC AVFs (P ¼ .017), and
3.23 mm in BVTs (P ¼ .912) at mean depths of 3.10 mm
(P ¼ .537) and 3.36 mm (P ¼ .695), respectively. No
statistical difference was seen in the percentage of male
patients in the pre-QI vs the QI group for any AVFs,
averaging 78% men for RC AVFs, 46% men for BC AVFs,
and 54% men for BVTs.
Patient compliance. All pre-QI follow-up appoint-
ment scheduling was left to the surgeon’s discretion,
whereas follow-up appointments in the QI period were
scheduled according to the protocol timeline. Compliance
with the ﬁrst postoperative appointment was deﬁned as
attending the appointment within 30 days of the operation.
In the pre-QI cohort, 53 patients (48%) attended the ﬁrst
appointment within 30 days; the average number of days to
the ﬁrst appointment was 41 6 43 days. In the QI cohort,
55 patients (65%) attended the ﬁrst appointment within
30 days (P ¼ .029); the average number of days to the ﬁrst
appointment was 33 6 18 days (P ¼ .099). According to
our protocol, the next mandated visit was a ﬁstulogram
within 40 days if indicated. Only two patients (12%) from
the pre-QI cohort underwent a ﬁstulogram within 40 days,
with an average number of days from AVF creation of
66 6 34 days. In comparison, 11 patients (33%) from the
QI cohort attended within 40 days (P ¼ .173), with an
average time of 57 6 29 days (P ¼ .324).
The second appointment attendance was assessed as
within 55 days of AVF creation. Of the pre-QI cohort,18 patients (25%) attended within 55 days, with the
average time to attendance of 77 6 27 days. Of the QI
cohort, 15 patients (23%) attended within 55 days
(P ¼ .842), with the average time to attendance of
77 6 28 days (P ¼ .907). Comparison of compliance
and notable patient outcomes are presented in Table II.
Patient-related outcomes. The average time to
permission to cannulate was 88 6 46 days in the pre-
QI cohort and 88 6 47 days (P ¼ .920) in the QI
cohort; only two pre-QI and three QI patients had
permission to cannulate before 4 weeks. When broken
down by access location, permission to cannulate for
pre-QI vs QI patients was 83 6 46 vs 100 6 47 days
(P¼ .285) for RCAVFs, 736 39 vs 756 41 days (P¼ .872)
for BC AVFs, and 116 6 43 vs 111 6 50 days (P ¼ .725)
for BVTs.
In the pre-QI cohort, 24 AVFs failed, making the fail-
ure to mature rate 22% compared with 18 failed AVFs
in the QI cohort, resulting in a failure rate of 21%
(P ¼ .862). Failure rates by location in pre-QI vs QI
were 19% vs 46% for RC AVFs (P ¼ .044), 21% vs 11%
for BC AVFs (P ¼ .264), and 26% vs 11% for BVTs
(P ¼ .282). The mean number of interventions after AVF
creation per access was 0.42 and 0.61 for the pre-QI and
QI groups, respectively (P ¼ .116). By access location,
the mean number of interventions per access in the
pre-QI vs QI group was 0.58 vs 0.57 in the RC AVFs
(P ¼ .941), 0.42 vs 0.65 in the BC AVFs (P ¼ .246), and
0.26 vs 0.58 in the BVTs (P ¼ .091). Table III presents
intervention data broken down by AVF location. The num-
ber of days between BVT creation and transposition
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Fig 4. Kaplan-Meier survival curve depicts loss of primary patency
in patients who underwent arteriovenous ﬁstula (AVF) creation
from January 1, 2012, through April 30, 2012 (before the quality-
improvement [pre-QI] initiative), and from January 1, 2013,
through April 12, 2013 (QI). Standard error of the mean<10% for
all time points.
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Fig 5. Kaplan-Meier survival curve depicts loss of secondary
patency in patients who underwent arteriovenous ﬁstula (AVF)
creation from January 1, 2012, through April 30, 2012 (before the
quality-improvement [pre-QI] initiative), and from January 1,
2013, through April 12, 2013 (QI). Standard error of the
mean <10% for all time points.
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56 6 27 days in the QI cohort (P ¼ .204).
Kaplan-Meier survival curves of primary and secondary
patency illustrate no statistical difference between the pre-
QI and QI cohorts (Figs 4 and 5). Although primary
patency was lost slightly earlier in the QI cohort, the
6-month end points and secondary patency end points
were not different. At 6 months, primary patency was
38.8% in the pre-QI group and 36.3% in the QI group
and secondary patency was 76.4% in the pre-QI group
and 74.4% in the QI group.
DISCUSSION
To meet the KDOQI guidelines and FFBI goals,
vascular surgeons, nephrologists, and ESRD networks
across the United States have made a concerted effort to
increase AVF creation and use to decrease morbidity and
mortality associated with ESRD and improve patient qual-
ity of life. Furthermore, future health care measures and
reimbursement will incorporate HD access type utilization
to assess dialysis units, creating a ﬁnancial incentive to
ensure the highest proportion of functional AVF
usage.14,15 Although the initial increase in AVF creation
did increase the percentage of HD patients in the United
States using an AVF as their primary vascular access, that
number has plateaued in recent years.16
Our group previously determined our AVF time to
maturation was much longer than the optimal 4- to
6-week maturation time quoted in the literature. Histori-
cally, our failure to mature rate of 20% was similar to other
studies, but our primary patency rates were lower than
those reported in the literature.7 The QI initiative
attempted to improve these outcomes and the time to
permission to cannulate by using a standardized protocol
outlining a follow-up schedule and hiring a patient liaisonto follow-up with patients and communicate with dialysis
units. Development of the protocol incorporated a litera-
ture review, current institutional protocols and those from
other ESRD networks, as well as collaboration between
vascular surgeons, ofﬁce and hospital management, and
dialysis unit managers to create an integrated, effective
follow-up protocol along KDOQI guidelines.
Although our time to permission to cannulate
improved compared with our historical time of 146 days,
the difference between the pre-QI and QI cohorts was
not statistically signiﬁcant. The improvement from the
2005 data we have previously published likely reﬂects the
effect of incorporating electronic medical records to
schedule and monitor patients and the more frequent use
of preoperative and postoperative duplex scanning. These
practice procedures were the same in the pre-QI and QI
cohorts. Our failure to mature and mortality rates were
also the same between the two study cohorts. The pre-
QI and QI cohorts had similar rates for AVF location,
but outcomes varied within those categories. BC AVFs
demonstrated the best outcomes overall in the QI cohort
in time to permission to cannulate and failure to mature,
which may be accounted for by the signiﬁcantly larger pre-
operative vein size. The only parameters that are widely
supported in the literature as signiﬁcant predictors of
AVF maturation or failure are size of the vein preopera-
tively and the surgeon’s expertise.17 Our ﬁndings regarding
vein size conﬁrm this conclusion. The effect of surgeon
expertise on any differences between the pre-QI and the
QI group were negligible because the same group of sur-
geons performed the surgeries during both time periods.
The lack of improvement in AVF time to permission to
cannulate and failure rates demonstrates poor overall AVF
outcomes in our patient population. In addition, we were
unable to assess whether the poor outcomes could have
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to cannulate or intervention for stenosis because a substan-
tial number of patients were not compliant with the
protocol.
Patient compliance has been recognized as a signiﬁcant
factor affecting patient outcomes in ESRD and HD. Kut-
ner et al18 found smoking and younger patient age were
indicators of poor compliance in HD and peritoneal dial-
ysis. Other studies have analyzed the obstacles preventing
adherence to dialysis regimens, including attending HD
sessions, taking medications, and following the recommen-
ded diet.19-22
Our study is the ﬁrst, to our knowledge, to assess
patient compliance in the AVF maturation period. Compli-
ance with AVF follow-up is an important aspect of timely
maturation to enable early recognition of stenosis or
thrombosis and to facilitate proper permission to cannu-
late.17 Because permission to use the AVF is given by the
vascular surgeon in our community, our goal in establish-
ing a standard follow-up schedule was to place patients
into the algorithm of “okay to use AVF,” “needs interven-
tion to mature,” or “needs to be abandoned and new
access creation” sooner, which requires patient compliance
with the follow-up schedule.
As the literature suggests, our hypothesis was that
improving patient follow-up compliance would improve
time to cannulation; however, as our report states, the
QI initiative was unable to improve patient compliance.
Thus, we cannot really investigate the effect that the imple-
mentation of the protocol had on AVF outcomes. Because
the QI initiative did not affect our poor patient compliance,
the protocol could not have had any effect on the time to
cannulation because a prerequisite of time to cannulation is
to have a follow-up visit to get permission to cannulate.
Although the QI signiﬁcantly increased the percentage
of patients who followed up within 30 days of AVF crea-
tion from 48% to 65%, the trend did not continue with a
ﬁstulogram within 40 days or second appointment in
55 days. Because most approvals to cannulate come at
the second appointment or later, this failure to enforce
timely follow-up >30 days limited the effect of the QI,
resulting in no signiﬁcant improvement in patient out-
comes. Without meeting our primary goal of facilitating
patient adherence to the follow-up protocol, assessing
whether designating and facilitating patient follow-up can
affect AVF time to maturation or failure is difﬁcult. In
fact, the intervention rate in the QI cohort was higher
than in the pre-QI cohort, meaning overall there was an
increase in intervention and cost without a resulting
improvement in AVF usage.
One important point to note is the demographic and
socioeconomic distribution of our target population.
Compared with nationwide ESRD network data, our
patient cohorts had a similar percentage of male patients;
however, our percentage of patients who were African
American, diabetic, and uninsured was the same or higher
than any of the networks and far higher than in Europe or
Japan.4,23 Furthermore, African American patients have thelowest rates of pre-ESRD nephrologist care, which is asso-
ciated with higher percentages of patients initiating dialysis
via a catheter5 and with poorer ﬁstula outcomes compared
with other races.24-26
In our study, the overall compliance with the ﬁrst
follow-up appointment within 30 days in the African-
American patient population was 55% at an average of
37 days from access creation, whereas compliance in the
Caucasian patient population was 66% (P ¼ .230) at an
average of 31 days from access creation (P ¼ .100).
Compliance with the second follow-up appointment was
22% at an average of 80 days from access creation in the
African American patient population and 37% (P ¼ .101)
at an average of 66 days from access creation (P ¼ .001)
in Caucasian patients. Overall time to permission to cannu-
late was 89 days with a failure to mature rate of 22% in the
African American patient population, whereas time to
permission was 88 days (P ¼ .880) with a failure rate of
21% (P ¼ .809) in the Caucasian patient population. The
African American and Caucasian cohorts were both 43%
female, whereas the overall mean age was 58 years for
African American patients vs 66 years for Caucasian
patients (P ¼ .002), and 70% vs 67% were already on
HD at the time of access creation (P ¼ .648).
ESRD networks with high-risk patient populations like
ours are especially motivated to implement KDOQI and
FFBI recommendations to improve their HD access out-
comes, but evidence of signiﬁcant improvement with use
of these techniques is scarce. The KDOQI exhorts imple-
mentation of multidisciplinary teams, integrating early
referral, best clinical practices, patient education, and sur-
veillance to provide the best and safest HD access to
patients. Logically, earlier referrals from nephrologists
should increase the percentage of patients initiating HD
with an AVF. Earlier referral is also expected to decrease
the number of patients already on HD who present to
vascular surgeons for an initial assessment, which was
disconcertingly high in our cohorts (68% in the pre-QI
and 66% in the QI cohort). However, some recent studies
have shown this may not translate into appreciable beneﬁts
in randomized controlled trials.9
Other groups have developed risk equations to predict
successful maturation or failure, with little ability to trans-
late these equations into clinical use.24,27 Several studies
defend the placement of AVFs in elderly, diabetic, or
female patients,28-30 whereas some groups contend an
AVG may be a valid alternative if it avoids long-term use
of TDCs.31,32 Even surveillance and monitoring tools
have not led to signiﬁcant beneﬁts.16,17 Overall, experts
agree the evidence inﬂuencing clinical practice of HD
access placement and maintenance is of very low quality.
This leaves practices trying different strategies and indepen-
dently assessing the effect the change has in their respective
populations.
Limitations of our study include its retrospective
nature, the small number of patients in each cohort, the
signiﬁcant number of patients who were lost to follow-
up, and the limited follow-up period of 6 months for the
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190 Lynch et al January 2015QI cohort. In addition, we did not assess patient factors
that caused the poor compliance, such as transportation,
inability to afford copay, and comorbid illness, among
others. Future studies should analyze these factors contrib-
uting to noncompliance that were anecdotally discussed
with our patient liaison, which may yield suggestions to
improve compliance.
Our results suggest two possible areas of improvement
for AVF patient outcomes. First, the high proportion of
patients undergoing initial HD access creation who were
already receiving HD through a catheter is a signiﬁcant
concern to our group. Although studies present conﬂicting
data on the possible beneﬁts of early access creation, it is
worth attempting to start these patients in access proceed-
ings earlier to realize the possible improvement of time to
permission to cannulate and failure rate.31,32 Catheter use
before AVF placement is associated with a higher rate of
AVF failure,23 which means most of our patient population
was already at a disadvantage in terms of AVF maturation
at the time of access creation. Hence, starting the proceed-
ings early is another AVF maturation factor left to improve
in our population to realize better outcomes for our
patients. This involves not only earlier referrals from
nephrologists but also earlier patient presentation to
nephrologists, which may not be within our power to inﬂu-
ence without large-scale patient education.
Second, reﬂecting on input our patient liaison has
received from patients and the difﬁculty with enforcing
patient follow-up at our clinic, we believe our surveillance
protocol needs to be re-evaluated to suit our patients, who
are dealing with dialysis appointments, cost of ofﬁce visits if
not yet on Medicare, transportation problems, or comorbid
health concerns. In addition, although Medicare, Medicaid,
and other insurers have reimbursed all ﬁstula maturation
duplex ultrasound assessments in our group, future legisla-
tion and reimbursement guidelines may preclude this prac-
tice. Integrating follow-up surveillance with nephrologist or
dialysis appointments to monitor AVF maturation has the
potential to make follow-up more patient-centered, cost-
effective, and hopefully, improve patient compliance.CONCLUSIONS
By instituting a QI initiative including a standardized
protocol and patient liaison, we hoped to decrease AVF
time to maturation and failure to mature rates. The QI
initiative signiﬁcantly increased the number of patients
complying with the ﬁrst 30-day follow-up appointment
after access creation. Despite this initial success, patient
compliance with a timely ﬁstulogram and the second
follow-up appointment was very poor and not inﬂuenced
by the QI initiative, thus limiting the functional effect of
the QI initiative on time to AVF maturation. Improving
AVF outcomes and use to the levels set by FFBI in our
population may necessitate a more integrated QI program,
including earlier referrals from nephrologists, failure to
mature deadlines, patient and community education, and
communication with dialysis units.AUTHOR CONTRIBUTIONS
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